A Single-arm, Prospective, Multi-center Study to Explore Maintained Efficacy With Ofatumumab Therapy in Patients With Relapsing Multiple Sclerosis Who Discontinue Intravenously Delivered Anti-CD20 Monoclonal Antibody (aCD20 mAb) Therapy (OLIKOS)
Latest Information Update: 05 Nov 2024
At a glance
- Drugs Ofatumumab (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms OLIKOS
- Sponsors Novartis Pharmaceuticals
- 01 Nov 2024 Planned End Date changed from 31 Jul 2024 to 31 Mar 2025.
- 18 Sep 2024 According to a Novartis Media Release, Data from the OLIKOS Phase IIIb study will be presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2024 Annual Meeting in Copenhagen, Denmark on September 18-20.
- 18 Sep 2024 Results published in the Novartis Media Release